Calprotectin - A Marker of Mortality in COPD? Results from a Prospective Cohort Study
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Calprotectin - A Marker of Mortality in COPD? Results from a Prospective Cohort Study. / Holmgaard, Dennis B; Mygind, Lone; Titlestad, Ingrid; Madsen, Hanne Birkemose; Pedersen, Svend Stenvang; Mortensen, Ole Hartvig; Pedersen, Court.
I: C O P D, Bind 10, Nr. 5, 11.07.2013, s. 581-587.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Calprotectin - A Marker of Mortality in COPD?
T2 - Results from a Prospective Cohort Study
AU - Holmgaard, Dennis B
AU - Mygind, Lone
AU - Titlestad, Ingrid
AU - Madsen, Hanne Birkemose
AU - Pedersen, Svend Stenvang
AU - Mortensen, Ole Hartvig
AU - Pedersen, Court
PY - 2013/7/11
Y1 - 2013/7/11
N2 - Abstract Calprotectin comprises more than 45% of the cytosolic content of neutrophil granulocytes. Because pathogenesis, disease activity and disease progression in COPD are believed to be partly dependent of neutrophil driven inflammation we decided to investigate whether plasma level of calprotectin (p-calprotectin) was associated with all-cause mortality in patients with COPD. We measured p-calprotectin in blood samples from 460 patients with moderate to very severe COPD in stable phase. Patients were stratified into three groups according to p-calprotectin level. Outcome measure was all-cause mortality. Analyses were adjusted for factors known to influence mortality using a Cox regression analysis. We found a time dependent correlation between p-calprotectin levels and mortality during the first 5 years of follow-up. Increasing levels of p-calprotectin were associated with concomitant increases in mortality from HR 1.56 (CI 95%: 1.03 -2.38) at calprotectin between 100 -200 ng/ml to HR 2.02 (CI 95%: 1.27-3.19) at calprotectin >200 ng/ml. P-calprotectin could be a useful marker of all-cause mortality in patients suffering from moderate to very severe COPD.
AB - Abstract Calprotectin comprises more than 45% of the cytosolic content of neutrophil granulocytes. Because pathogenesis, disease activity and disease progression in COPD are believed to be partly dependent of neutrophil driven inflammation we decided to investigate whether plasma level of calprotectin (p-calprotectin) was associated with all-cause mortality in patients with COPD. We measured p-calprotectin in blood samples from 460 patients with moderate to very severe COPD in stable phase. Patients were stratified into three groups according to p-calprotectin level. Outcome measure was all-cause mortality. Analyses were adjusted for factors known to influence mortality using a Cox regression analysis. We found a time dependent correlation between p-calprotectin levels and mortality during the first 5 years of follow-up. Increasing levels of p-calprotectin were associated with concomitant increases in mortality from HR 1.56 (CI 95%: 1.03 -2.38) at calprotectin between 100 -200 ng/ml to HR 2.02 (CI 95%: 1.27-3.19) at calprotectin >200 ng/ml. P-calprotectin could be a useful marker of all-cause mortality in patients suffering from moderate to very severe COPD.
U2 - 10.3109/15412555.2013.781580
DO - 10.3109/15412555.2013.781580
M3 - Journal article
C2 - 23844942
VL - 10
SP - 581
EP - 587
JO - C O P D
JF - C O P D
SN - 1541-2555
IS - 5
ER -
ID: 49787666